Neuropeptide W-23(human)(TFA)

首页蛋白库基因库产品会员服务

位置：首页 > 产品库 > Neuropeptide W-23(human)(TFA)

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

NPW-23 TFA

Neuropeptide W-23 (human) (NPW-23) TFA 是 Neuropeptide W 的主要活性形式，为NPBW1 (GPR7)和NPBW2 (GPR8)的内源性激动剂。

生物活性

Neuropeptide W-23 (human) (NPW-23) TFA, the active form of Neuropeptide W, is an endogenous agonist ofNPBW1 (GPR7)andNPBW2 (GPR8)^[1].

IC₅₀& Target

NPBW1, NPBW2^[1]

体外研究
(In Vitro)

Neuropeptide W-23 (human) (NPW-23) increases the I_Ca,Lin transfected human embryonic kidney 293 cells and VSMCs via GPR7^[1].
Neuropeptide W-23 (human) increases the expression of pan phospho-PKC, intracellular diacylglycerol level, and the second messenger catalyzed by PLC^[1].

体内研究
(In Vivo)

Neuropeptide W-23 (human) (NPW-23) (0.3-3.0 nM; intracerebroventricular injection; 2 μL) increases total behavioral activity, including locomotion and grooming in conscious rats^[2].
Neuropeptide W-23 (human) (NPW-23) (2-8 nM; i.c.v.; 10 μL) shows anorexigenic effect in rats^[3].

Animal Model:	Male Harlan Sprague-Dawley rats, 250–300 g^[2]
Dosage:	0.3, 1.0 and 3.0 nM
Administration:	Intracerebroventricular injection, 2 μL
Result:	Caused significant increases in mean arterial pressure. Demonstrated a significant increase in total activity, ambulatory activity, and duration of stereotypy.

Animal Model:	Male Wistar rats weighing 250–300 g^[3]
Dosage:	2, 4, 6 and 8 nM
Administration:	Intra-cerebroventricular injection, 10 μL
Result:	Decreased dark feeding and fasting-induced feeding, decreased feeding intake and weight gain.

分子量

2697.04

Formula

C₁₂₂H₁₈₅F₃

Sequence

Trp-Tyr-Lys-His-Val-Ala-Ser-Pro-Arg-Tyr-His-Thr-Val-Gly-Arg-Ala-Ala-Gly-Leu-Met-Gly-Leu

Sequence Shortening

WYKHVASPRYHTVGRAAGLMGL

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.